Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
about
A patient-centred approach to biological treatment decision making for psoriasis: an expert consensusPsoriasis registries worldwide: systematic overview on registry publications.A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values.Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trialImprovements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.Review of 103 Swedish Healthcare Quality Registries.Patient-reported outcomes in the Swedish National Quality Registers.Health-related quality of life in patients with psoriasis: a systematic review of the European literature.Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity.Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study.Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
P2860
Q28082166-B6432D97-95F0-455B-8C8D-E2373518F966Q30251454-1FCA9CE1-7ED5-4757-BCCF-CF571270378AQ35846824-EADD6074-5365-4B5C-8FD3-104A0B62E725Q36413344-B87EE31A-3F53-4C2C-A909-6B15B147F8E0Q36628064-91BF4459-44EA-42E8-A84F-22F0AD3BAE7CQ36746549-191089F7-E522-4637-8179-08D346125A38Q37257450-CA694985-6B5C-4DAB-8F9E-04D4176176EEQ37295966-5FEED59E-939C-4D83-B4DD-7B4AEAACB9D4Q37601452-7B15BF9B-9E8A-4ECD-9F8F-4B7AD7C755EEQ38244987-1347CCB2-62BF-4498-A794-DE4FEA2EAD4BQ38573721-9860875C-2D91-43C4-BDDE-D1F877400D10Q38853236-27294DA0-331D-4315-8960-E37B285B42E4Q38993275-5F771CEA-A1B4-4611-82FB-1B0E4ADE4355Q39078782-5975D6B7-3A69-4EEF-A716-45C4A112670AQ39498625-44538E52-C04C-4AF2-AB59-9472F6262CC7Q39546109-C767CC30-C05C-4AB9-8F7A-5CA44D001F77Q40209526-A6EED7E6-04F8-4795-8EEF-67050B37A9EBQ40261663-E108D7F2-EF76-4598-BB73-3450AC8D391BQ40585781-EC5F4660-8DE7-43EA-A98D-B6CB9CEE9056Q47595988-01B2DF64-A750-472D-A39B-C3C21D5EBAB3Q47883565-D392340A-2102-4321-9EE5-573AE86D6EF8
P2860
Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Switch to biological agent in ...... tcomes in real-world practice.
@en
Switch to biological agent in ...... tcomes in real-world practice.
@nl
type
label
Switch to biological agent in ...... tcomes in real-world practice.
@en
Switch to biological agent in ...... tcomes in real-world practice.
@nl
prefLabel
Switch to biological agent in ...... tcomes in real-world practice.
@en
Switch to biological agent in ...... tcomes in real-world practice.
@nl
P356
P1433
P1476
Switch to biological agent in ...... utcomes in real-world practice
@en
P2093
Jenny M Norlin
Ulf Persson
P304
P356
10.1159/000345715
P577
2012-01-01T00:00:00Z